Overall, these results suggest that GLP‐1RAs might be associated with a decreased risk of CRC compared to several traditional antidiabetic treatments, with significant findings particularly noted against insulin, TZD, and SGLT2 inhibitors. This evidence concerns the gene INS and colorectal carcinoma.